Director, Oncology Strategic Pricing and Contracting at Corcept Therapeutics

Redwood City, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Oncology, BiotechnologyIndustries

Requirements

Strong background in oncology pricing, contracting, and reimbursement; experience with oral oncology therapies and community practices required
Experience with infused/ASP products is a plus
Demonstrated ability to analyze payer contracting scenarios and provide “go/no-go” recommendations
Excellent analytical skills and ability to communicate business relevant insights coming out of these analyses
A history of work requiring strong attention to detail

Responsibilities

Lead development of and execute post-launch pricing and contracting strategies for relacorilant in oncology. Support adoption in community oncology practices with in-practices dispensing capabilities with appropriate contracting
Analyze and provide strategic recommendations to pricing governance bodies regarding customer contract and deal proposals
Analyze pricing and reimbursement for pharmacy and medical products such as nab-paclitaxel and competitive products in the platinum resistant ovarian cancer (PROC) market
Implement processes to ensure that accurate records are kept and decisions are appropriately documented. Ensure that records are secure and backed up
Partner with Finance, Endocrinology, and Oncology leadership to operationalize contract execution, distribution agreements, payer contracts, and GPO membership management
Partner with Finance to manage contracting with government customers including the VA, DoD, PHS/340b and stage Medicaid programs. Implement processes to ensure accurate and timely government price reporting complying with government agency requirements
Own the GTN forecast process and collaborate with Finance and Brand leadership to ensure reliable net sales forecasts for quarterly close and long-range planning
Work with Brand, Analytics & Insights, and Finance partners to support quarterly forecasts, providing data-driven input and surfacing risks/opportunities
Uphold Corcept’s Key Principles by driving collaboration, embracing possibilities, following the data, and leading by doing, ensuring all initiatives align with the Company’s ethics and patient-first principles

Skills

Strategic Pricing

Contracting

Pricing Strategy

Contract Analytics

Deal Analytics

Contract Operations

Gross to Net

Market Access

Brand Forecasting

Oncology Contracting

Payer Contracting

Provider Contracting

Reimbursement Analysis

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free